-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
-
Summary
-
AbCellera Biologics Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q1 2021 to Q2 2024.
- AbCellera Biologics Inc. Income Tax Expense (Benefit) for the quarter ending June 30, 2024 was -$11.3M, a 50.6% decline year-over-year.
- AbCellera Biologics Inc. Income Tax Expense (Benefit) for the twelve months ending June 30, 2024 was -$25.5M, a 970% decline year-over-year.
- AbCellera Biologics Inc. annual Income Tax Expense (Benefit) for 2023 was -$27.6M, a 134% decline from 2022.
- AbCellera Biologics Inc. annual Income Tax Expense (Benefit) for 2022 was $80.6M, a 22.7% increase from 2021.
- AbCellera Biologics Inc. annual Income Tax Expense (Benefit) for 2021 was $65.7M, a 68.8% increase from 2020.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)